Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004154 · ClinicalTrials.gov registry record · Phase 3
Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT00004154: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00004154 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004154, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether fenretinide is more effective than a placebo in preventing the recurrence of bladder cancer after surgery to remove the tumor. PURPOSE: This randomized phase III trial is studying fenretinide to see how well it works compared to a placebo in treating patients who are at risk for recurrent bladder cancer following surgery to remove the tumor.
Interventions
- OTHER Placebo
- DRUG Fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 1998-07-30 |
| Est. Completion | 2005-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004154
The ClinicalTrials.gov registry entry for NCT00004154 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00004154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004154 about?
NCT00004154 is a clinical study titled "Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer". RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether fenretinide is more effective than a placebo in preventing the recurrence of bladder cancer...
What is the current status of trial NCT00004154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 1998-07-30. Estimated completion is 2005-03-01.
What interventions are being tested in trial NCT00004154?
The interventions under investigation include: Placebo (OTHER), Fenretinide (DRUG).
Who is sponsoring clinical trial NCT00004154?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.